Prevalence and risk factors of HTLV-1/2 and other blood borne infectious diseases among blood donors in Yaounde Central Hospital, Cameroon

Prevalence and risk factors of HTLV-1/2 and other blood borne infectious diseases among blood donors in Yaounde Central Hospital, Cameroon

Michel Kengne^1,&, Dorine Carol Wouado Tsata¹, Thérèse Ndomgue^1,2, Julius Mbekem Nwobegahay^1,3

 

¹Department of Medical Microbiology and Immunology, School of Health Sciences-Catholic University of Central Africa, Yaoundé Cameroon, ²Assistant Laboratory Technicians School, Yaoundé, Cameroon, ³Military Health Research Center (CRESAR), Yaounde, Cameroon

 

 

^&Corresponding author
Michel Kengne, Department of Medical Microbiology and Immunology, School of Health Sciences-Catholic University of Central Africa, Yaoundé Cameroon

 

 

 

 

The risk of viral and bacterial infections constitutes the major cause of transfusion related morbidity and mortality. Although the risk of transfusion-transmitted infections today is lower than ever due to the current efforts and strategies that have greatly helped reduce transfusion-associated risks [1], the supply of safe blood products remains subject to contamination with known and yet to be identified human pathogens [2, 3]. According to UNAIDS (1997), up to 4 million blood donations worldwide are not tested each year for human immunodeficiency virus (HIV) and few are tested for hepatitis B and C viruses [4]. In sub-Saharan countries, blood safety remains an issue of major concern in transfusion medicine where national blood transfusion services and policies, appropriate infrastructure, trained personnel and financial resources are inadequate. Data on blood donors screening have revealed a high prevalence for the presence of viral and bacterial markers indicative of HBV, HIV, HCV and syphilis infections [5]. Similarly, those infections have been reported to be prevalent in Cameroon [6] and the screening of blood donors for HB surface antigen (HBsAg), HCV, HIV and syphilis antibodies is henceforth a routine practice in the blood banks [7].

Although a priority is given to screen blood for antigens and antibodies of the cited infectious agents in our set up, continuous monitoring of the magnitude of transfusion-transmissible infections among blood donors is important for assessing the occurrence of infections in the blood donor's population and for estimating the epidemiology of the diseases in the community. Aside from HIV, HCV, HBV and syphilis, a number of other infectious agents transmitted by transfusion of blood products have been described. Human T cell lymphotropic viruses I is (HTLV-I) associated with adult T cell leukemia and HTLV-associated myelopathy/ tropical spastic paraparesis [8]. Both retroviruses (HTLV-1/2) have been attributed a role in the increased risk for developing severe asthma, respiratory and urinary tract infections, uveitis and dermatitis [9-12]. The global epidemiology of HTLV varies widely with prevalence rates up to 10% in certain areas in Japan, and up to 5-6 % in countries of the Caribbean, the Sub-Saharan Africa, and areas in the Middle East and South America [12]. In our set up, no priority has ever been given to screen blood donors for antibodies to HTLV-1/2 [7] thereby making blood transfusion unsafe for blood recipients. Thus, evaluation of data on the prevalence of these transfusion transmitted infectious agents among blood donors is important for estimating the risk of transfusion and optimizing donor recruitment strategies to minimize infectious diseases transmission due to these viruses namely HTLV-1/2. Therefore, this study was conducted to determine among blood donors at the Yaounde Central Hospital in Cameroon, the seroprevalence of HTLV, HIV, HCV, HBsAg, and syphilis and to determine the epidemiological correlates, if any, in the occurrence of HTLV infection.

 

 

This was a cross sectional and prospective study which was carried out in the blood bank unit of the Yaounde Central Hospital in Cameroon between June and November 2014. The hospital is a tertiary level hospital that provides health services to over twenty thousand inhabitants in the capital city, Yaounde. A consecutive sample of 265 apparently healthy adult blood donors agreed to participate after an informed consent. Participants were either volunteers or family donors who were recruited by patients, their families or friends to replace blood used or expected to be used for patients from the blood bank of the hospital. Confidentiality was ensured at all stages of the study. A unique identification code was assigned to each participant. A designed questionnaire was used to collect data from individuals over a panel of questions on the past history of blood transfusion, sexual behavior and practice, medical and sociodemographic histories. For each study subject, five milliliters of blood was collected and sera from all the blood donors were then checked for the presence of hepatitis B surface antigen (HBsAg) and the antibodies to HIV-1/2, HCV and syphilis using the automated system i1000SR immunoassay (abbot) following the manufacturer's instructions. Similarly, antibodies to HTLV-1/2 were detected using ELISA technique (HTLV-1/2 ELISA 4.0, CE MARK, MP Biomedicals, France) according to the manufacturer's instructions. ABO and Rh blood groups determinations were carried out on a slide using monoclonal blood grouping antisera; anti-A, anti-B, anti-AB and anti-D (BIOTEC Laboratories Ltd, Great Britain) following the manufacturer's instructions.

 

Data analysis: data were entered and analyzed using SPSS version 16.0 for windows (SPSS, Inc, Chicago, IL). Discrete variables were compared using the Chi-square test. Statistical significance difference was considered at value of p<0.05.

 

Ethics: a written informed consent was obtained from the study subjects prior to enrollment. Permission to conduct the study was obtained from the Director of the Yaoundé Central Hospital; while ethical clearance was obtained from the institutional ethics committee of the School of Health Sciences, Catholic University of Central Africa (N°2015/006/CEIRSH/ESS/MIM).

 

 

As shown in Table 1, a total of 265 consecutive apparently healthy adult blood donors were screened at the blood bank unit of the Yaoundé Central hospital during the study period. Donors were aged between 18 and 52 years (mean 28±6.6 years) and 184 (69.4%) were in the age group of 18-30 years. Of these, 242 (91.30%) were males compared to 23 (8.7 %°) females (sex ratio M/F = 10:1), 159 (60%) were workers, 114 (43.0%) had a secondary level of education, 189 (71.3%) lived in urban areas, 222 (83.8%) were unmarried, 117 (44.2%) were first time donors, 235 (88.7%) were voluntary donors, 140 (52.8%) were blood group O and 252 (95.0%) were Rhesus D positive. 77 (29.05%) of the blood donors had serological evidence of infection with at least one pathogen and 4 (5.2%) had dual infections with HTLV-1/2. The overall prevalence of HTLV-1/2, HIV, HCV, HBV and syphilis were 5.7%, 5.3%, 2.6%, 11.7%, 3.8% respectively (Table 2). The differences in the prevalence of HTLV-1/2 between the age group, sex, profession, educational level, residence, marital status, donor status, type of donors and rhesus/ABO blood group of the donors were not statistically significant (P > 0.05) (Table 1). Statistically significant association was observed between HTLV-1/2 infection and the following factors such as surgical history of the blood donors (Chi²=4.785; P=0.029), scarification (Chi²=6.359; P=0.012), piercing (Chi²=16.353; P=0.000) and intravenous drug use (Chi²=15.660; P=0.000) (Table 3).

 

 

This study aimed at determining the prevalence and risk factors of HTLV-1/2 and other blood borne infectious diseases among blood donors in the Yaounde Central Hospital of Cameroon. According to WHO recommendations, the minimum requirement for all donor blood should include screening for HIV, HBV and syphilis [6]. A national strategy of infectious disease screening of donated blood is well implemented in the blood bank unit of the Yaounde Central Hospital in Cameroon and includes the testing for HIV, HBV, HCV, and T. pallidium. Screening for HTLV-1/2 is not routine in this center thus the anti HTLV-1/2 test that was used in this study was purchased. In our study, the overall prevalence of HTLV-1/2, HIV, HCV, HBV and syphilis were 5.7%, 5.3%, 2.6%, 11.7%, 3.8% respectively. This result is in agreement with those reported in Africa [6, 7, 13, 14]. The prevalence of HBV was remarkedly high among the study population. It has been extensively reported a very large burden of HBsAg infection in all sub-Saharan African regions with carrier rates ranging from 9 to 20% [14]. Our finding may be due to the low hepatitis B vaccine coverage rates in the study set up. This study illustrates the current transfusion transmissible risk of the screened infectious agents in Cameroon and raises serious concerns regarding the safety of the blood supply in our community, even after the screening of donors for infectious agents. There is still a potential risk of transmitting viral infections during the serologic window period i.e. the period of early infectivity when an immunologic test is non-reactive [15]. Therefore, the absence of infectious agents in the blood of apparently healthy individuals may not be sufficient to ensure lack of circulating pathogens.

In a study conducted in India by Bhattacharya et al [16], it was observed that out of the 1027 HBsAg negative blood samples screened, 18.3% were found to be anti-HBc positive and 21.3% of the anti-HBc positive samples were HBV DNA positive by PCR. This figure should serve as a remainder to health personnel to take the necessary precautions, including reducing the number of unnecessary transfusions that will help to lower the risk of the most frequent transfusion transmitted infections to blood recipients. To explore the risk factors for HTLV-1/2 seropositivity, we examined sociodemographic and lifestyle variables among blood donors. It was found that HTLV-1/2 infection was not associated to age, sex, profession, educational level, residence, marital status, donor status, and type of donors. The same trend wasn't observed in other studies. For example, in studies carried out by Douardo et al [17] and Santos et al [18], age was found to be a risk factor for HTLV-1 infection. A potential explanation for this association was that increasing age provides a greater length of exposure to events that might result in acquiring the virus, such as sexual activity, intravenous drug use or blood transfusion [18]. The difference in the size of the study population may explain the discrepancy with our result. In this study, we observed that individuals with surgical history, scarification, piercing and who used intravenous drug are at higher risk for HTLV-1/2 infection. This result is in agreement with the finding of Blattner [19] who demonstrated that HTLV-1 is transmitted by routes involving transfusion and needle sharing.

 

 

This study illustrates the current transfusion transmissible risk of HTLV-1/2, in the study set up. The data also reveal that individuals with surgical history, scarification, piercing and who used intravenous drug are at higher risk for HTLV-1/2 infection. From these observations, we recommend routine screening of blood donor for HTLV-1/2 antibodies.

 

 

The authors declare no competing interests.

 

 

Michel Kengne conceived, designed, financed the study and produced the first draft of this manuscript. Dorine Carol Wouado Tsata and Thérèse Ndomgue performed the sample collection, the laboratory assays and the data analysis and interpretation. Julius Mbekem Nwobegahay corrected the research proposal before the study and did a thorough review of the manuscript. All authors have revised the manuscript in its current form.

 

 

Special thanks are due to the Director of the Yaounde Central Hospital who granted the research authorization for this study.

 

 

Table 1: sociodemographic characteristics of the study subjects and correlates with HTLV-1/2 infection

Table 2: prevalence of blood borne pathogens among blood donors

Table 3: factors associated with HTLV-1/2 infection

 

 

1. Schmunis G, Zicker F, Cruz JR, Cuchi P. Safety of blood supply for infectious disease in Latin American countries, 1994-1997. Am J Trop Med Hyg. 2001; 65(6): 924-930. PubMed | Google Scholar


2. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996; 334(26): 1685-1690. PubMed | Google Scholar


3. Pillonel J, Laperche S, Saura C, Desenclos JC, Courouce AM. The transfusion-transmissible agents working group of the French Society of Blood Transfusion, Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion. 2002; 42(8): 980-988. PubMed| Google Scholar


4. UNAIDS. Blood safety and HIV: Technical update, Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland. UNAIDS. October 1997; 2-4. Google Scholar


5. Sarkodie F, Adarkwa M, Adu-Sarkodie Y, Candotti D, Acheampong JW, Allain JP. Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sang. 2001; 80(3): 142-147. PubMed | Google Scholar


6. Mbanya DN, Takam D and Ndumbey PM. Serological findings amongst first-time blood donors in Yaounde, Cameroon: is safe donation a reality or a myth. Transfus Med. 2003; 13(5): 267-273. Google Scholar


7. Tayou Tagny C, Diarra A, Yahaya R, Hakizimana M, Nguessan A, Mbensa G, Nébié Y, Dahourou H, Mbanya D, Shiboski C, Murphy E and Lefrère JJ. Characteristics of blood donors and donated blood in sub-Saharan Francophone Africa. Transfusion. 2009; 49(8): 1592-1599. PubMed | Google Scholar


8. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet. 1999; 353(9168): 1951-1958. PubMed | Google Scholar


9. Murphy EL, Glynn SA, Fridey J, Sacher RA, Smith JW, Wright DJ, Newman B, Gibble JW, Ameti DI, Nass CC, Schreiber GB, Nemo GJ. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I and II-infected blood donors, Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect. 1997; 176(6): 1468-1475. PubMed | Google Scholar


10. Murphy EL, Wang B, Sacher RA, Fridey J, Smith JW, Nass CC, Newman B, Ownby HE, Garratty G, Hutching ST, Schreiber GB. Respiratory and urinary tract infections, arthritis and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect. 2004; 10(1): 109-116. PubMed


11. Roucoux DF, Murphy EL. The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. 2004; 6(3): 144-154. PubMed | Google Scholar


12. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005; 24(39): 6058-6068. PubMed | Google Scholar


13. Hunsmann G, Bayer H, Schneider J, Schmitz H, Kern P, Dietrich M, Buttner DW, Goudeau AM Kuekarni G and Fleming AF. Antibodies to ATLV/HTLV-1 in Africa. Med Microbiol immunol. 1984; 173(3): 167-170. PubMed | Google Scholar


14. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut. 1996; 38(Suppl 2): S5-S12. PubMed | Google Scholar


15. Bihl F, Castelli D, Marincola F, Dodd YR and Brander C. Transfusion-transmitted infections. Journal of Transl Med. 2007; 5: 25. PubMed | Google Scholar


16. Bhattacharya P, Chandra PK, Datta S, Banerjee A, Chakraborty S, Rajendran K, Basu SK, Bhattacharya SK, Chakravarty R. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection. World J Gastroenterol. 2007; 13(27): 3730-3733. PubMed


17. Dourado I, Alcantara LCJ, Barreto ML, da Gloria TM, Galvão-Castro B. HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics. J Acquir Immune Defic Syndr. 2003; 34(5): 527-31. PubMed | Google Scholar


18. Santos RF, Conceição GC, Martins MS, Kraychete A, Penalva MA, Carvalho EM, Lopes AA, Rocha PN. Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-1) among maintenance hemodialysis patients. BMC Nephrol. 2017; 18(1): 64. PubMed | Google Scholar


19. Blattner WA. T-lymphotropic viruses and diseases of long latency. Ann Intern Med. 1989; 111(1): 4-6. PubMed | Google Scholar